@brakestar7
actief 1 uur, 48 minuten geleden
n terms of antiviral effectiveness in patients with mild to moderate COVID-19. Furthermore, the combination of RBV and LPV/r is associated with a significant increase in gastrointestinal adverse events, suggesting that RBV and LPV/r should not be co-administered to COVID-19 patients simultaneously.
http://www.ClinicalTrials.gov, ID […] Bekijken
Sorry, er is geen activiteit gevonden. Probeer een ander filter.